Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Kaori Matsumoto, Tetsuya Hasegawa, Kosuke Ohara, Tomoyo Kamei, Junichi Koyanagi & Masayuki Akimoto. (2021) Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyer–Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active metabolite, 6-methoxy-2-naphthylacetic acid in vitro. Xenobiotica 51:2, pages 155-166.
Read now
Read now
Kaori Matsumoto, Tetsuya Hasegawa, Kosuke Ohara, Chihiro Takei, Tomoyo Kamei, Junichi Koyanagi, Tamiko Takahashi & Masayuki Akimoto. (2020) A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes. Xenobiotica 50:7, pages 783-792.
Read now
Read now
Sophia M. Shi & Li Di. (2017) The role of carbonyl reductase 1 in drug discovery and development. Expert Opinion on Drug Metabolism & Toxicology 13:8, pages 859-870.
Read now
Read now
Iva Boušová, Lenka Skálová, Pavel Souček & Petra Matoušková. (2015) The modulation of carbonyl reductase 1 by polyphenols. Drug Metabolism Reviews 47:4, pages 520-533.
Read now
Read now
Petra Malátková & Vladimír Wsól. (2014) Carbonyl reduction pathways in drug metabolism. Drug Metabolism Reviews 46:1, pages 96-123.
Read now
Read now
Articles from other publishers (27)
Hiroyuki Ichida, Tatsuki Fukami, Takashi Kudo, Kenji Mishiro, Shiori Takano, Masataka Nakano, Gaku Morinaga, Akiko Matsui, Naoki Ishiguro & Miki Nakajima. (2023) Identification of HSD17B12 as an enzyme catalyzing drug reduction reactions through investigation of nabumetone metabolism. Archives of Biochemistry and Biophysics 736, pages 109536.
Crossref
Crossref
Anselm Morell, Youssif Budagaga, Dimitrios Vagiannis, Yu Zhang, Lenka Laštovičková, Eva Novotná, Andrew Haddad, Melodie Haddad, Ramon Portillo, Jakub Hofman & Vladimír Wsól. (2022) Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters. Archives of Toxicology 96:12, pages 3265-3277.
Crossref
Crossref
Xianglin Chu, Siyu He, Yang Liu, Yijun Liu, Feng Feng, Qinglong Guo, Li Zhao & Haopeng Sun. (2022) Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): Functions, regulation, and structural insights of inhibitors. Chemico-Biological Interactions 351, pages 109746.
Crossref
Crossref
Satoshi Endo, Toshiyuki Matsunaga & Toru Nishinaka. (2021) The Role of AKR1B10 in Physiology and Pathophysiology. Metabolites 11:6, pages 332.
Crossref
Crossref
Yiding Hu, Yi Xiao, Zhesui Rao, Vasant Kumar, Hanlan Liu & Chuang Lu. (2021) Carbon-carbon Bond Cleavage Catalyzed by Human Cytochrome P450 Enzymes: α-ketol as the Key Intermediate Metabolite in Sequential Metabolism of Olanexidine. Drug Metabolism Letters 14:1, pages 41-53.
Crossref
Crossref
Donald J. AbrahamDeepak K. Dalvie & Bernard Testa. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
139
.
Yaohui Li, Rongzhen Zhang & Yan Xu. (2021) Structure-based mechanisms: On the way to apply alcohol dehydrogenases/reductases to organic-aqueous systems. International Journal of Biological Macromolecules 168, pages 412-427.
Crossref
Crossref
Anselm Morell, Eva Novotná, Jaroslav Milan, Petra Danielisová, Neslihan Büküm & Vladimír Wsól. (2020) Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism. Archives of Toxicology 95:1, pages 67-78.
Crossref
Crossref
Anselm Morell, Lucie Čermáková, Eva Novotná, Lenka Laštovičková, Melodie Haddad, Andrew Haddad, Ramon Portillo & Vladimír Wsól. (2020) Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3. Cancers 12:12, pages 3731.
Crossref
Crossref
Tássia S. Tavares, Jakub Hofman, Alžběta Lekešová, Jana Želazková & Vladimír Wsól. (2020) Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3. Cancers 12:11, pages 3127.
Crossref
Crossref
Eva Novotná, Anselm Morell, Neslihan Büküm, Jakub Hofman, Petra Danielisová & Vladimír Wsól. (2020) Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?. Archives of Toxicology 94:9, pages 3059-3068.
Crossref
Crossref
Ales Sorf, Simona Sucha, Anselm Morell, Eva Novotna, Frantisek Staud, Alzbeta Zavrelova, Benjamin Visek, Vladimir Wsol & Martina Ceckova. (2020) Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors. Cancers 12:6, pages 1596.
Crossref
Crossref
Yukuang Guo, Hyunwoo Lee & Hyunyoung Jeong. 2020. The Microbiome in Health and Disease. The Microbiome in Health and Disease
61
93
.
Tomoyo Kamei, Yuta Kimura, Jyunichi Koyanagi, Kaori Matsumoto, Tetsuya Hasegawa, Masayuki Akimoto & Tamiko Takahashi. (2019) Determination of the Absolute Configuration of the Nabumetone Metabolite 4-(6-Methoxy-2-naphthyl)butan-2-ol Using the Chiral Derivatizing Agent, 1-Fluoroindan-1-carboxylic Acid. Chemical and Pharmaceutical Bulletin 67:1, pages 75-78.
Crossref
Crossref
Eva Novotná, Neslihan Büküm, Jakub Hofman, Michaela Flaxová, Etela Kouklíková, Dagmar Louvarová & Vladimír Wsól. (2018) Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment. Biochemical Pharmacology 156, pages 22-31.
Crossref
Crossref
Lucie Zemanová, Palani Kirubakaran, Ignacio Hernando Pato, Hana Štambergová & Jiří Vondrášek. (2017) The identification of new substrates of human DHRS7 by molecular modeling and in vitro testing. International Journal of Biological Macromolecules 105, pages 171-182.
Crossref
Crossref
Petra Malátková, Adam Skarka, Kateřina Musilová & Vladimír Wsól. (2017) Reductive metabolism of tiaprofenic acid by the human liver and recombinant carbonyl reducing enzymes. Chemico-Biological Interactions 276, pages 121-126.
Crossref
Crossref
Svatopluk Světlík, Martin Štícha, Olga Matoušková, Lenka Nespěšná, Zbyněk Sklenář, Aleš Bartůněk, František Perlík & Ondřej Slanař. (2016) Nabumetone and 6-MNA Pharmacokinetics, Assessment of Intrasubject Variability and Gender Effect. American Journal of Therapeutics 23:6, pages e1498-e1503.
Crossref
Crossref
Petra Malátková, Matthildi Kanavi, Milan Nobilis & Vladimír Wsól. (2016) In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chemico-Biological Interactions 258, pages 153-158.
Crossref
Crossref
Petra Malátková, Simona Sokolová, Lucie Chocholoušová Havlíková & Vladimír Wsól. (2016) Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases. Biochemical Pharmacology 109, pages 83-90.
Crossref
Crossref
Jakub Hofman, Adam Skarka, Jana Havrankova & Vladimir Wsol. (2015) Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases. Biochemical Pharmacology 96:3, pages 168-178.
Crossref
Crossref
Rudolf Andrýs, Lucie Zemanová, Juraj Lenčo, Zuzana Bílková & Vladimír Wsól. (2015) Carbonyl-reducing enzymes as targets of a drug-immobilised affinity carrier. Chemico-Biological Interactions 234, pages 169-177.
Crossref
Crossref
Kaori Matsumoto, Tetsuya Hasegawa, Tomoyo Kamei, Junichi Koyanagi, Tamiko Takahashi, Masayuki Akimoto & Kenji Sugibayashi. (2014) Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. European Journal of Drug Metabolism and Pharmacokinetics 40:2, pages 127-135.
Crossref
Crossref
Petra Malátková, Lucie Havlíková & Vladimír Wsól. (2014) The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chemico-Biological Interactions 220, pages 241-247.
Crossref
Crossref
Fatbardha Varfaj, Siti N. A. Zulkifli, Hyoung-Goo Park, Victoria L. Challinor, James J. De Voss & Paul R. Ortiz de Montellano. (2014) Carbon-Carbon Bond Cleavage in Activation of the Prodrug Nabumetone. Drug Metabolism and Disposition 42:5, pages 828-838.
Crossref
Crossref
Stephen M.F. Jamieson, Yongchuan Gu, Donya Moradi Manesh, Jad El-Hoss, Duohui Jing, Karen L. MacKenzie, Christopher P. Guise, Annika Foehrenbacher, Susan M. Pullen, Juliana Benito, Jeffrey B. Smaill, Adam V. Patterson, Medhanie A. Mulaw, Marina Konopleva, Stefan K. Bohlander, Richard B. Lock & William R. Wilson. (2014) A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells. Biochemical Pharmacology 88:1, pages 36-45.
Crossref
Crossref
Lucie Skarydova, Radana Tomanova, Lucie Havlikova, Hana Stambergova, Petr Solich & Vladimir Wsol. (2014) Deeper Insight into the Reducing Biotransformation of Bupropion in the Human Liver. Drug Metabolism and Pharmacokinetics 29:2, pages 177-184.
Crossref
Crossref